2023 U.S.-Booked Air Volume: $33.7 million
2023 U.S. T&E: $78 million
2023 European T&E: $86.2 million
2023 Companywide T&E: $290.8 million
Primary Airline Suppliers: Delta, Lufthansa, United
Primary Hotel Suppliers: Accor, Hilton, Marriott
Primary Rental Car Suppliers: Enterprise, Sixt
Primary Global Online Booking Tool: SAP Concur
Primary Global Expense Supplier: SAP Concur
Primary Global Payment Provider: American Express
Primary Global Travel Risk Management Provider: MD Medicus
Consolidated Global TMC: BCD
Global pharmaceutical and biotechnology
company Bayer spent $33.7 million on U.S.-booked air travel in 2023, slightly
lower than the $35.2 million reported in 2022. Domestic volume accounts for 34
percent of all travel.
Bayer's new CEO started in June 2023, and
in January 2024, the company announced a new operating model called Dynamic
Shared Ownership with the aim to reduce hierarchies, eliminate bureaucracy and
accelerate decision-making processes.
There were no travel policy changes in
2023, and the policy review in 2024 will be in line with the DSO model.
The company does not anticipate returning
to pre-pandemic levels of business travel or to being fully back in the office
for several years. Internal travel was 41 percent in 2023, down from 51 percent
in 2022 and higher than the 35 percent projected for 2024.
Bayer in 2023 reduced its relevant Scope
3 greenhouse gas emissions, which include business travel, by about 4.3 percent
compared with its base year of 2019. Its goal is to reduce such emissions from
2019 levels by an absolute 12.3 percent by 2029. The company's GHG emissions
for business travel totaled about 190,000 metric tons of CO2 equivalents in
2023 compared with about 150,000 for 2022 and about 300,000 in 2019.
Company sales in 2023 totaled nearly €47.6
billion, down about 6 percent year over year. Bayer also as of Dec. 31, 2023,
employed more than 99,700 people, down from nearly 101,400 in 2022.